Oxybutynin chloride: Alterations in drug delivery and improved therapeutic index

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 4, 2002, Pages 443-454

  Dmochowski, Roger ^a   Kell, Sherron ^a   Staskin, David ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Oxybutynin chloride; Pharmacotherapy; Urinary incontinence

Indexed keywords

CYTOCHROME P450 3A4; DESETHYLOXYBUTYNIN; DRUG METABOLITE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PHENYLCYCLOHEXYLGLYCOLIC ACID; PLACEBO; TOLTERODINE; UNCLASSIFIED DRUG; WATER; MANDELIC ACID DERIVATIVE;

ASTHENIA; BLADDER DYSFUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG METABOLISM; DRUG RELEASE; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FIRST PASS EFFECT; GASTROINTESTINAL TOXICITY; HUMAN; LIVER METABOLISM; MEMBRANE PERMEABILITY; NAUSEA; OSMOSIS; PATIENT COMPLIANCE; REVIEW; SOMNOLENCE; URGE INCONTINENCE; URINARY TRACT INFECTION; URINE INCONTINENCE; XEROSTOMIA; ANIMAL; BLOOD; HOSPITALIZATION; METHODOLOGY; STATISTICS;

ANIMALS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; HUMANS; MANDELIC ACIDS; SEVERITY OF ILLNESS INDEX; URINARY INCONTINENCE;

EID: 0036240759     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.4.443     Document Type: Review

References (46)

1. Epidemiology and etiology of urinary incontinence in the elderly
2. R and S enantiomers of oxybutynin: Pharmacological effects in guinea-pig bladder and intestine
3. 3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis, and salivary secretion in guinea-pigs
4. Comparison of calcium antagonist properties of antispasmodic agents
5. Depressant action of oxybutynin on the contractility of intestinal and urinary tract smooth muscle
6. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability
7. Oxybutynin chloride inhibits proliferation and suppresses gene expression in bladder smooth muscle cells
8. The pharmacokinetics of oxybutynin in man
9. Metabolism of oxybutynin: Establishment of desethyloxybutynin and oxybutynin N-oxide formation in rat liver preparation using deuterium substitution and gas chromatographic mass spectrometric analysis
10. Pharmacological profile of DDO1 and desethyloxybutynin (DEOB) - The major metabolite of tolterodine and oxybutynin (OB) respectively
11. Measurement of oxybutynin and its N-desethyl metabolite in plasma and its application in pharmacokinetic studies in young, elderly, and frail elderly volunteers
12. Comparison of oxybutynin and its active metabolite, N-desethyloxybutynin, in the human detrusor and parotid gland
13. Metabolism of drugs and other xenobiotics in the gut lumen and wall
14. Characterization of interintestinal variations in human CYP3A dependent metabolism
15. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis
16. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: A meta analysis
17. Tolterodine - A new bladder selective muscarinic agent
18. Oxybutynin-induced heat stroke in an elderly patient
19. Influences of tropsium chloride and oxybutynin on quantitative EEG in healthy volunteers
20. Electrophysiological evaluation of potential adverse drug effects of tolterodine, oxybutynin and trospium chloride on the central nervous system
21. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride
22. Oxybutynin and cognitive dysfunction
23. Central nervous system adverse events with anticholinergic medication for overactive bladder
24. A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance
25. Intravesical application of oxybutynin: Mode of action in controlling detrusor hyperreflexia. Preliminary results
26. The pharmacokinetics of intravesical and oral oxybutynin chloride
27. In vitro intravesical installation of anitcholinergic, antispasmodic and calcium channel blocking agents (rabbit whole bladder model)
28. Intravesical oxybutynin for neurogenic bladder dysfunction: Less systemic side effects due to reduced first pass metabolism
29. Lack of effect of food on the pharmacokinetics of an extended release oxybutynin formulation
30. The effect of pH on drug release from extended release formulations of oxybutynin and tolterodine
31. Effect of doing time on the total intestinal transit time of non-disintegrating systems
32. Pharmacokinetics of an oral once a day controlled release oxybutynin formulation compared with immediate release oxybutynin
33. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate
34. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride
35. Comparison of CYP3A4 inhibitor effects on the stereoselective pharmacokinetics of extended release oxybutynin and conventional oxybutynin
36. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence
37. Dry mouth with conventional and controlled release oxybutynin in urinary incontinence
38. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence
39. Quantitative characterization of therapeutic index: Application of mixed effects modeling to evaluate oxybutynin dose efficacy and dose side effect relationships
40. Prospective randomized controlled trial of extended release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT trial
41. Randomized double blind study to compare extended release oxybutynin and tolterodine for overactive bladder
42. A randomized controlled trial comparing the efficacy of controlled release oxybutynin tablets (10 gm once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were of oxybutynin
43. Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled release tablet
44. One year, prospective, open label trial of controlled release oxybutynin for overactive bladder in a community based population
45. Controlled release oxybutynin for overactive bladder in an elderly population
46. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder